

**Notice of Allowability**

Application No.

10/807,326

Examiner

Patricia Hightower

Applicant(s)

NAGANO ET AL.

Art Unit

1711

*-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--*

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1.  This communication is responsive to the amendment filed February 17, 2006.2.  The allowed claim(s) is/are 1,2,4 and 5.3.  Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).a)  All    b)  Some\*    c)  None    of the:1.  Certified copies of the priority documents have been received.2.  Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.3.  Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\* Certified copies not received: \_\_\_\_\_.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

**THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.**4.  A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.5.  CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.(a)  including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached  
1)  hereto or 2)  to Paper No./Mail Date \_\_\_\_\_.(b)  including changes required by the attached Examiner's Amendment / Comment or in the Office action of  
Paper No./Mail Date \_\_\_\_\_.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).

6.  DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.**Attachment(s)**

1.  Notice of References Cited (PTO-892)
2.  Notice of Draftsperson's Patent Drawing Review (PTO-948)
3.  Information Disclosure Statements (PTO-1449 or PTO/SB/08),  
Paper No./Mail Date \_\_\_\_\_
4.  Examiner's Comment Regarding Requirement for Deposit  
of Biological Material
5.  Notice of Informal Patent Application (PTO-152)
6.  Interview Summary (PTO-413),  
Paper No./Mail Date \_\_\_\_\_.
7.  Examiner's Amendment/Comment
8.  Examiner's Statement of Reasons for Allowance
9.  Other \_\_\_\_\_.

***Reasons For Allowance***


The following is an examiner's statement of reasons for allowance: In view of the applicants' amendment/remarks filed February 17, 2006 in which it has been established that the independent claims 1,2,5 (as currently amended) requires that the adamantane ring be bonded directly or indirectly to three carboxylic acid groups and to "Y4-Xa" whrein Y4 is a single bond or a bivalent aromatic cyclic group and Xa is a hydrogen atom or a hydrocarbon group; Aoi does not fairly suggest the inventive configuration wherein the adamantane ring is bonded directly or indirectly to three carboxylic acid groups and to "Y4-Xa" wherein Y4 is a single bond or a bivalent aromatic cyclic group and Xa is a hydrogen atom or a hydrocarbon group; thus the rejection of the claims under 35 USC 102(a,e) Aoi have been withdrawn. Further, the obviousness-type double patenting rejection over copending application 10/807,426 has been withdrawn because the '426 application in Formula (1) requires at least one of X and R1-R3 id derivatized; the compound of formula (1) in the instant application is not derivatized. Also, the aromatic polyamine denoted by formula (2) of '426 application is characterized by at least one R5-R8 being protected by a protection group. The compound of formula (2) in the instant application does not have any protecting groups. Thus, claims 1-2, and 4-5 are allowable.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Patricia Hightower whose telephone number is (571) 272-1073. The examiner can normally be reached on M-F from 9:30 A.M. - 6:00 P.M.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Seidleck can be reached on (571) 272-1078. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

  
Patricia H. Hightower  
Primary Examiner  
Art Unit 1711

P. Hightower:ph  
March 18, 2006